CClinicalTrials.gg
CompletedNCT00419497Updated Sep 20, 2016

Paleolithic Diet in the Treatment of Glucose Intolerance

A Phase 2/3 interventional study of Paleolithic diet vs Mediterranean diet in Hyperglycemia and Coronary Heart Disease, sponsored by Lund University Hospital. Completed at 1 site in Sweden. Open to male participants. Per ClinicalTrials.gov, last updated 2016-09-20.

Sponsored by Lund University Hospital · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Sex
Male
01

Study summary

The purpose of this study is to determine whether a paleolithic diet improves glucose tolerance and insulin sensitivity in people with coronary heart disease and impaired glucose tolerance.

Read the detailed description

There is uncertainty about the optimal diet in the prevention and treatment of glucose intolerance and diabetes type 2, disorders which are very common in patients with coronary heart disease (CHD). Earlier studies have generally focused on intakes of fat, carbohydrate, fiber, fruit and vegetables. Another approach compares foods that were available during human evolution with more recently introduced ones. Twenty-nine CHD patients with glucose intolerance or diabetes have been randomized to 1) a Paleolithic ("Old Stone Age") diet (n=14) based on lean meat, fish, fruit, vegetables, root vegetables, eggs, and nuts, or 2) a Consensus (Mediterranean-like) diet (n=15) based on whole grains, low-fat dairy products, vegetables, fruit, fish, and oils and margarines generally assumed to be healthy. Primary outcome variables are changes during 12 weeks in weight, waist circumference, and area under the curve for glucose (AUC Glucose0-120) and insulin (AUC Insulin0-120) at the oral glucose tolerance test.

02

Conditions studied

  • Hyperglycemia
  • Coronary Heart Disease

Keywords

  • Paleolithic diet
  • Mediterranean-style diet
  • Glucose tolerance
  • Diabetes type 2
  • Weight loss
  • Waist
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 29 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Lund University Hospital is the lead sponsor of 64 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Hyperglycemia
  • Coronary Heart Disease
  • Increased waist circumference

Exclusion criteria

Exclusion Criteria:

  • Body mass index \<20 kg/m2
  • Serum creatinine >130 µmol/L
  • Poor general condition
  • Dementia
  • Unwillingness/inability to prepare food at home (by study participant or partner)
  • Participation in another medical trial
  • Chronic inflammatory bowel disease
  • Drug treatment with hypoglycemic agents
  • Drug treatment with warfarin
  • Drug treatment with oral steroid
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Paleolithic diet vs Mediterranean diet

    Prudent diets with or without grains and dairy

    Behavioral: Paleolithic diet vs Mediterranean diet

Interventions

  • BehavioralPaleolithic diet vs Mediterranean diet

    Prudent diets with or without grains and dairy

06

What researchers measure

Primary outcomes

  1. change in weight and waist circumference

    Time frame: 12 weeks

  2. area under the curve for glucose (AUC Glucose0-120) at the oral glucose tolerance test

    Time frame: 12 weeks

  3. area under the curve for insulin (AUC Insulin0-120) at the oral glucose tolerance test

    Time frame: 12 weeks

Secondary outcomes

  1. fasting plasma glucose

    Time frame: 12 weeks

  2. 30-min plasma glucose

    Time frame: 12 weeks

  3. 120-min plasma glucose

    Time frame: 12 weeks

  4. fasting plasma insulin

    Time frame: 12 weeks

  5. 30-min plasma insulin

    Time frame: 12 weeks

  6. 120-min plasma insulin

    Time frame: 12 weeks

07

Study locations

1 site
  • Lund University Hospital
    Lund, 22185, Sweden
08

References and documents

Publications

  • Lindeberg S, Jonsson T, Granfeldt Y, Borgstrand E, Soffman J, Sjostrom K, Ahren B. A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. Diabetologia. 2007 Sep;50(9):1795-1807. doi: 10.1007/s00125-007-0716-y. Epub 2007 Jun 22. PubMed 17583796 ↗
  • Jonsson T, Granfeldt Y, Erlanson-Albertsson C, Ahren B, Lindeberg S. A paleolithic diet is more satiating per calorie than a mediterranean-like diet in individuals with ischemic heart disease. Nutr Metab (Lond). 2010 Nov 30;7:85. doi: 10.1186/1743-7075-7-85. PubMed 21118562 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00419497
Lead sponsor
Lund University Hospital
Responsible party
Staffan Lindeberg (Ass prof, Lund University Hospital) — Principal investigator
First posted
Jan 8, 2007
Start date
Jan 2003
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Sep 20, 2016

Study contacts

Staffan Lindeberg, MD PhD
principal investigator · Department of Clinical Sciences, IKVL 1, Lund University, Lund Sweden

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion